Dear DPA members and colleagues,
As we continue to deal with the ongoing challenges brought on by COVID-19, I wanted to take a moment to reach out on behalf of the DPA. I especially want to thank all of our members who are pathologists, laboratory technicians, researchers and other medical professionals who are truly on the front lines in this fight. We appreciate the difficulties you face working in this environment and honor your ongoing commitment to patients.
I do not need to reiterate that this is a serious situation which we are all in together. Please rest assured that DPA leadership is working diligently to best serve our members and the entire digital pathology community.
It is important to lean on each other for assistance. We strongly encourage you to let us know what your needs are and we will do our best to help. Should you have any questions, concerns and/or needs, please do not hesitate to contact us.
Thank you for what you do for your communities. Please continue to stay safe and healthy.
DPA Remote Pathology Letter
Validation of a digital pathology system including remote review during the COVID-19 pandemic
Liron Pantanowitz: The importance of digital pathology
Remote Sign-Out of Cases With Digital Pathology FAQs
FDA Coronavirus Disease 2019 (COVID-19)
CDC Coronavirus (COVID-19)
WHO Coronavirus Roadmap V9
AJCP Covid Safety considerations March 2020
Autopsy and COVID-19
Clinical Characteristics of Coronavirus Disease 2019 in China
Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)
COVID-19: what is next for public health?
Infection prevention and control for COVID-19 in healthcare settings - first update
Complete routine remote digital pathology services
Guidance for Remote Reporting of Digital Pathology Slides During Periods of Exceptional Service Pressure: An Emergency Response from the UK Royal College of Pathologists
Enforcement Policy for Remote Digital Pathology Devices During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency
Post‐mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction
Adapting and Preparing for Remote Digital Signout During the Time of COVID-19
COVID-19 and the Cytology Lab (Do's and Dont's)
Enforcement Policy for Personal Protective Equipment (PPE) During COVID-19: Immediately in Effect Guidance
Updated guidance for Clinical Trials:
European Medicines Agency/ European Commission:
U.S. Food and Drug Administration: